Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAMS4CL: Systemic Therapeutic Regimens for Cutaneous Leishmaniasis
NCT07463040Phase 3Not yet recruiting
- Sponsor
- Institute of Tropical Medicine Antwerp
- Start
- Jan 2027
- Primary completion
- Mar 2029
- Modality
- Lipid-based Nanoparticles, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of miltefosine, paromomycin, liposomal amphotericin b, pentamidine in cutaneous leishmaniasis (CL), sponsored by Institute of Tropical Medicine Antwerp. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
miltefosineparomomycinliposomal amphotericin bpentamidine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT07463040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463040.